BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart and upcoming early data in Netherton syndrome.
Gayer described BioCryst as a rare disease commercialization company led by ORLADEYO, an oral prophylactic therapy for HAE that generated $602 million in revenue last year. He said the drug’s performance reflects both its differentiated oral profile and the company’s patient-focused commercialization approach.
